Trial Profile
A randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of venlafaxine ER in adult outpatients with major depressive disorder(B2411263)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2021
Price :
$35
*
At a glance
- Drugs Venlafaxine (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 28 Oct 2015 Primary endpoint has not been met. (Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination (Flexible dose)), as per an article published in the International Clinical Psychopharmacology
- 28 Oct 2015 Primary endpoint has been met. (Change From Baseline in 17-item Hamilton Raing Scale for Depression (HAM-D17) Total Score at Week 8 or Early Termination (Fixed-dose)), as per an article published in the International Clinical Psychopharmacology
- 28 Oct 2015 Results published in the International Clinical Psychopharmacology